Update 7 november 2011: Als u klikt op deze link ziet u de lopende studies bij borstkanker in Nederland. Het zal duidelijk zijn dat er weinig studies zijn naar niet toxische behandelingen en medicijnen, terwijl juist bij borstkanker leefstijl en voeding en extra vitamines en mineralen een belangrijke rol kunnen spelen. Ook niet belastende behandelingen als electro hyperthermie en immuuntherapeutische aanpak zijn niet in de onderzoekslijsten te vinden. Wel enkele studies naar het effect van ondersteuning in het psycho-sociale vlak.
Persoonlijke opmerking: zouden al die mensen die geld geven aan het KWF en/of meedoen aan acties eigenlijk wel weten dat een zeer klein gedeelte naar onderzoek naar niet toxische stoffen en behandelingen gaat en het overgrote deel naar weer nieuwe niet bewezen chemo's?
Hieronder de lijst van lopende wetenschappelijke studies bij borstkanker in Europa zoals die staan geregistreerd bij de EORTC. Voor sommige trials worden nog patienten gezocht, bij de meeste studies is die al vol. Als u op het nummer in de eerste kolom klikt krijgt u het studieprotocol te zien en hoe u zich eventueel kunt aanmelden. Meestal gebeurt dat in overleg met uw oncoloog maar u kunt ook zelf contact opnemen met betreffende studieleiders.
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 10085 |
Clinical and biological characterization of Male Breast Cancer : an international retrospective EORTC, BIG and NABCG intergroup study. |
| 10071 |
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer |
| 10055 |
Phase III Trial Evaluating the role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (age 66 year or older) with Endocrine Non-responsive Breast Cancer who are NOT suitable for being Offered a "Standard Chemotherapy Regimen". |
| 10054 |
A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for locally advanced breast cancer. |
| 10041 |
MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid Chemo Therapy): A prospective, randomized study comparing the 70-gene signature with the common clinicpathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes" |
| 10053 |
Pharmacokinetics study of combined treatment Lapatinib and Tamoxifen in advanced/metastatic breast cancer |
| 10031 |
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (SOFT). |
| 16023 |
Phase I study of lonafarnib (SCH66336) in combination with Herceptin plus paclitaxel in HER-2 neu overexpressing breast cancer. |
| 10012 |
An IDBBC single arm phase II trial evaluating the activity of Iressa (ZD 1839) in metastatic breast cancer patients pretreated with an antiestrogen and a nonsteroidal aromatase inhibitor (anastrozole or letrozole). |
| 10021 |
An EORTC randomized, double blind, placebo controlled, Phase II multi-center trial of anastrozole (Arimidex) in combination with ZD1839 (Irissa(R)) or placebo in patients with advanced breast cancer. |
| 10002 |
A survey of the Breast International Group (B.I.G.) to assess the attitude of patients aged less than 35 years, with early breast cancer, toward the risk of loss of fertility related to adjuvant therapies. |
| 10001 |
A randomized phase II-III trial evaluating the efficacy of capecitabine and vinorelbine in anthracycline and taxane pre-treated metastatic breast cancer. |
| 10995 |
A Phase II Study of CMF in Combination with Anti c-erbB2 antibody (HerceptinR) in Women with c-erbB2 positive Metastatic Breast Cancer |
| 10974 |
LAMANOMA: Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomized phase III study. |
| 10003 |
An EORTC-BG-IDBBC/ECSG phase II study evaluating the role of the multi-drug resistance (MDR) reversor, R101933, in patients with taxane refractory metastatic breast cancer. |
| 10994 |
First prospective Intergroup Translational Research Trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane versus a non taxane regimen. |
| 10992 |
Habits Hormonal replacement therapy after breast cancer diagnosis - is it safe? Protocol for randomized clinical study concerning hormonal replacement therapy (HRT) after previous radical breast cancer treatment. |
| 10983 |
A Phase III randomized double blind study of letrozole versus placebo in women with primary breast cancer completing five or more years of adjuvant Tamoxifen (NCIC CTG MA.17, EORTC study 10983) |
| 10993 |
A randomised phase II study of two different schedules of Caelyx in metastatic breast cancer |
| 10991 |
EORTC-IDDBC Phase I study of Capecitabine (Xeloda) in combination with Epirubicin and cyclophosphamide (CEX) as primary treatment of large operable or locally advanced/inflammatory breast cancer. |
| 05971 |
A multicenter randomized trial, with direct individual benefit, to determine the optimal circadian time of Vinorelbine administration combined with chronomodulated infusion of 5-Fluorouracil in previously treated patients with metastatic breast cancer. |
| 10967 |
Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant Exemestane treatment with further Tamoxifen. |
| 10961 |
Doxorubicin / Taxol as first line chemotherapy in advanced breast cancer : a randomized study versus standard Doxorubicin / Cyclophosphamide combination regimen. A phase II study leading to a phase III. |
| 22922 |
Phase III randomized trial investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I-III breast cancer (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group EORTC 22922/10925) |
| 10932 |
Phase III study of evaluation of breast irradiation in early stage, low risk breast cancer patients after complete tumor excision (Joint study of the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Cooperative Group) |
| 04951 |
Phase II first line chemotherapy study with docetaxel (taxotere - RP56976) in patients with metastatic breast cancer |
| 15931 |
An international field study of the reliability and validity of the EORTC QLQ-C30 (v. 3.0) and a disease-specific questionnaire module (the QLQ-BR23) in assessing the quality of life of patients with breast cancer |
| 10941 |
Open, non-randomized parallel-group, phase II study of Liarozole Fumarate in patients with advanced breast cancer |
| 10924 |
Double-blind randomized phase III multicentre trial comparing the effect of oral pamidronate (CGP 23339A - Aredia) with placebo in patients with newly diagnosed bone metastases from breast cancer |
| 10920 |
An EORTC randomized phase III trial aiming at defining the role of short-term intensive chemotherapy at the time of isolated loco-regional relapse in breast cancer patients |
| 04931 |
A phase II first line chemotherapy study with docetaxel (RP56976) in patients with metastatic or locally advanced breast cancer |
| 10923 |
Taxol versus Doxorubicin as first line chemotherapy in advanced breast cancer: A randomized phase II study with crossover |
| 10921 |
A multicentre randomized phase III study of dose-intensive chemotherapy as primary treatment in a multimodality approach for locally advanced inflammatory breast cancer |
| 16921B |
Phase II trial with Taxotere in patients with breast cancer |
| 04924 |
A phase II first line chemotherapy study with taxotere (RP56976) in patients with metastatic or locally advanced breast cancer |
| 10912 |
Open phase II study of the nonsteroidal aromatase inhibitor, R 83 842 in postmenopausal women with advanced breast cancer (second line treatment). |
| 16902B |
Phase II trial of Elsamitrucin (BMY 28090) in patients with advanced breast cancer |
| 10901 |
Randomized phase III study of adjuvant chemotherapy followed by adjuvant Tamoxifen versus nil for patients with operable breast cancer |
| 16893B |
Phase II trial of GR63178A in patients with advanced breast cancer |
| 16892B |
Phase II trial of 4'-iodo-4'-deoxydoxorubicin in patients with advanced breast cancer |
| 10832 |
Phase III trial on the comparison between the alternative and sequential administration of three non-cross-resistant chemotherapy regimens ( CMF, ADM-DBD, CDDP-VDS ), in combination with Tamoxifen in advanced breast cancer. |
| 22881 |
Phase III study in the conservative management of breast carcinoma by tumorectomy and radiotherapy: assessment of the role of a booster dose of radiotherapy (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group) |
| 10881 |
Randomized phase III study of LHRH-agonist versus LHRH-agonist plus Tamoxifen versus Tamoxifen alone in the treatment of premenopausal advanced breast cancer |
| 16871B |
Phase II study of duP 785 (NSC 368390) in patients with advanced breast cancer |
| 04872 |
Randomized pilot study of idarubicin per os (4-dmDNR-IMI 30) in advanced breast cancer. Evaluation/comparison of leukopenia. Comparaison des deux modes d'administration dans les cancers avancés du sein. |
| 10871 |
A RANDOMIZED PHASE II TRIAL OF Doxorubicin IN DIFFERENT DOSAGES AND SCHEDULES FOR ADVANCED BREAST CANCER, USED IN SECOND LINE IN CMF REFRACTORY PATIENTS. |
| 10863 |
Phase III study of continuous Tamoxifen versus intermittent Tamoxifen versus alternating Tamoxifen and MPA. First line endocrine therapy for postmenopausal patients with advanced breast cancer. |
| 16864A |
Phase II Chemotherapy with Flavone Acetic Acid in Patients with Advanced Breast Cancer Resistant to Conventional Chemotherapy and Hormonal Therapy (Summary Last Modified 03/88) |
| 10861 |
Randomized phase III trial of second line endocrine treatment of postmenopausal patients with advanced breast cancer |
| 10854 |
Phase III trial of perioperative adjuvant chemotherapy in Breast Cancer |
| 10852 |
Phase III trial of short versus long term chemotherapy with CMF in postmenopausal patients with advanced breast cancer. |
| 10850 |
PHASE III TRIAL ON OPERABLE BREAST CANCER IN THE ELDERLY. TUMOR EXCISION PLUS Tamoxifen COMPARED WITH RADICAL MASTECTOMY |
| 10851 |
PHASE III TRIAL ON OPERABLE BREAST CANCER IN THE ELDERLY: Tamoxifen ALONE COMPARED WITH MODIFIED RADICAL MASTECTOMY |
| 16841B |
Phase II Chemotherapy with Menogaril in Patients with Advanced Breast Cancer |
| 10835 |
Assessment of Cyclic combination chemotherapy with estrogenic recruitment in advanced breast cancer: a phase III and double blind study. |
| 10762 |
Phase III trial of CMF versus CMF-TAM (tamoxifen)in postmenopausal women with advanced breast cancer |
| 10791 |
Phase II trial of PALA in advanced breast cancer |
| 10792 |
Phase III trial to assess the contribution of cytotoxic chemotherapy (CMF) and/or endocrine therapy (prednisolone/tamoxifen) to the primary treatment by radiotherapy of locally advanced breast cancer |
| 10802 |
Phase III trial of low dose versus high dose MPA (medroxyprogesterone acetate) in advanced breast cancer |
| 10803 |
Phase II trial of cisplatin plus vindesine in advanced breast cancer |
| 10805 |
Phase II trial of carminomycin and adriamycin in advanced breast cancer |
| 10806 |
Phase II trial of AZQ in advanced breast cancer |
| 16818 |
Phase II trial of 9, 10, anthracenedi-carbotaldehyde in advanced breast cancer |
| 10833 |
Randomized phase II trial of mitoxantrone and adriamycin for advanced breast cancer |
| 10834 |
Phase II trial on second line endocrine treatment of postmenopausal patients with advanced breast cancer |
| 16832 |
Randomized phase II trial of TNO-6 and CBDCA in advanced breast cancer |
| 16832B |
Randomized phase II trial of CHIP and CBDCA in advanced breast cancer |
| 16835D |
Phase II trial of TGU for patients with advanced breast cancer |
| 16911B |
Phase II trials with Leurubicin in patients with advanced breast cancer. |
| 16912B |
Phase II trial with rhizoxin in patients with advanced breast cancer. |
| 09771 |
Phase III adjuvant trial of CMF or no treatment after surgery and radiotherapy in N+ primary breast cancer |
| 10807 |
Phase II trial for the assessment of cyclic combination chemotherapy with estrogenic recruitment in advanced breast cancer |
| 10808 |
Phase III trial of classical CMF versus three-monthly intravenous CMF in postmenopausal patients with advanced breast cancer |
| 16854A |
Phase II trial of TCNU in patients with advanced breast cancer |
| 10742 |
Tamoxifen in premenopausal patients with advanced breast cancer |
| 10811 |
Phase II-III trial of 4'epi-adriamycin vs adriamycin in advanced breast cancer |
| 10821 |
Pilot study on long-term preoperative chemotherapy in high risk breast cancer |
| 16826 |
Randomized phase II trial of 4-demethoxydoxorubicin and deoxydoxorubicin in advanced breast cancer |
| 10761 |
Phase III trial of postoperative CMF (cyclophosphamide/methotrexate/5-FU) plus levamisole or placebo in N+ primary breast cancer |
| 10804 |
Phase II trial of 9-hydroxy-2N-methyl ellipticinium in advanced breast cancer |
| 16962B |
Phase II trial with LU 103793 in patients with breast cancer |
| 16943B |
Phase II trail with carzelesin in patients with Breast Cancer |
| 16944B |
Phase II trial with GI 47211 in patients with advanced breast cancer |
| 16802 |
Phase II trial of carminomycin and 4'epiadriamycin in advanced breast cancer |
| 10741 |
Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer |
| 10743 |
Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer (excluded from 10741) |
| 10751 |
Evaluation of a post-surgical alternating cyclical hormonal-cytotoxic therapy for patients with primary breast cancer of poor prognosis |
Gerelateerde artikelen
- Richtlijnen hoe uitgezaaide borstkanker met lage HER2 expressie (+1 of +2) te behandelen met of Sacituzumab govitecan of trastuzumab deruxtecan is door een team van deskundigen in een officieel rapport vastgelegd
- Richtlijnen in Amerika hoe borstkanker te behandelen met Her2 positieve receptoren op basis van recente wetenschappelijke studies
- Niet alle borstkankerpatienten hebben chemo of bestraling nodig omdat zij meer en krachtigere immuuncellen (TIL) hebben die de borstkanker automatisch opruimt.
- Leverresectie voor aan borstkanker gerelateerde levermetastasen geeft een mediane ziektevrije overleving van 50 maanden en een 5-jaars overleving van 65 procent
- 80 procent van patiënten met borstkanker met DCIS – ductaal carcinoma in situ - zouden kunnen volstaan met alleen een operatie, maar zonder bestraling post operatief of zelfs met een wait-and-see beleid
- Regelmatig uitvoeren van FDG-PET / CT scan voor monitoring van effecten van behandelingen bij uitgezaaide borstkanker signaleert eerder resistentie en kan sneller verandering van behandelingen bewerkstelligen.
- Maagzuurremmers tijdens en na de behandeling van kanker lijkt gerelateerd aan een verminderd geheugen en concentratie bij overlevenden van borstkanker
- Koud kussen - cool pad pillow topper - vermindert opvliegers en sterk transpireren met meer dan de helft in de nacht bij borstkankerpatienten die hormoontherapie gebruiken en verbetert daardoor het slapen copy 1
- Melkzuurbacterien - probiotica aanwezig in gezond borstweefsel beschermt vrouwen tegen borstkanker blijkt uit kleinschalige studie copy 1
- Verschil in status en afwijkende mutaties tussen primaire tumor en uitzaaiingen bij borstkanker komt vaker voor - ca. 20 procent - dan gedacht blijkt uit biomoleculaire profile studie
- Borsttumoren vergen vaak andere behandeling dan eerste behandelplan na second opinion aldus het Alexander Monro Ziekenhuis in Bilthoven in de Telegraaf
- Borstkanker kliniek Alexander Mono ziekenhuis in Bilthoven opent volgende maand de deuren. Ziektekosten verzekeraars erkennen en betalen specialistische zorg in prive kliniek
- Borstbesparende ingreep gevolgd door bestraling geeft betere kans op overleving - 13 procent - dan borstamputatie, vooral bij hormoongevoelige borstkanker blijkt uit grote langjarige studie
- Algemeen - Wetenschappelijk onderzoek bij borstkanker: Overzicht van lopende fase I, II, III studies bij borstkanker in Nederland en Europa.
- Algemeen: Borstkankerpatienten met DICS (ductaal in situ) - overleven steeds langer zonder recidief door adekwate behandelingen, blijkt uit grote langjarige gerandomiseerde studie.
- Algemeen:screening via periodieke mammografie geeft weinig tot geen invloed op cijfers van sterfte aan borstkanker, blijkt uit groot onderzoek van WHO in landen die vroeger en later bevolkings screening toe gingen passen, zoals bv. Nederland en Belgie.
- Algemeen: bij vrouwen met uitgezaaide borstkanker blijkt status van ER, PR en HER2-Neu vaak verschillend (bij 48,6%) en ook vaak te veranderen en vereist soms nieuwe behandelingsstrategie. Aldus gerandomiseerde studie. Artikel geplaatst 12 mei 2010
- Algemeen: Uitzaaiingen van primaire borstkanker of tumoren bij het ontstaan van een recidief van voormalig primaire borstkanker kunnen een andere receptor status hebben en hebben dus andere behandeling nodig
- Algemeen: Biopt uit schildwachtklier bij borstkanker veroorzaakt niet significant meer uitzaaiingen in lymfklieren of elders in lichaam dan zonder biopt, aldus gerandomiseerde studie bij 2502 vrouwen.
- Algemeen: ook minieme uitzaaiingen leiden vaker tot recidief van borstkanker, aldus Nederlands onderzoek
- Algemeen: Overgewicht vergroot risico op uitzaaiingen bij borstkanker en vergroot significant risico op overlijden aan borstkanker met 38%, blijkt uit groot bevolkingsonderzoek
- Algemeen: Borstkanker korte algemene informatie
Plaats een reactie ...
Reageer op "Algemeen - Wetenschappelijk onderzoek bij borstkanker: Overzicht van lopende fase I, II, III studies bij borstkanker in Nederland en Europa."